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Abstract (250 words max), now 257  
Background The clinical course of advanced adrenocortical carcinoma (ACC) is 
heterogeneous. The primary objective of our study was to refine and progress in the 
prognostic stratification of advanced ACC.  
Methods Patients with advanced ENS@T stage III or with synchronous stage IV ACC 
registered between 2000 and 2009 in the ENS@T databasis were enrolled. Primary endpoint 
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was overall survival (OS). Parameters with potential prognostic relevance were captured. 
Univariate and multivariate analyses were performed: model 1 “prior surgery”; model 2 "post 
surgery".  
Results Four hundred and forty-four patients with advanced ENS@T (stage III: 210; stage IV 
234 patients) were analysed. After a median follow-up of 55.2 months, median overall 
survival was 24 months. A modified ENS@T (mENS@T) classification was validated as 
defined by: stage III in case of invasion in surrounding tissues/organs or vena renalis/cava 
or, stage IVa, IVb, IVc in case of  2, 3 or >3 metastatic organs including the N, respectively. 
Five yr OS was 49%, 15%, 11% and 0% for mENSAT stages III, IVa, IVb and IVc , 
respectively (p<0.0001). At multivariate analysis, mENS@T stage (HR:2.6, HR:3.8 or HR:4.9 
for stage IVa, IVb, or IVc respectively, all p<0.0001) and 4 additional parameters were 
significantly associated to OS: age>50 years (HR:1.6, p<0.0001), presence of tumor or 
hormonal-related symptoms (HR:1.6, p=0.01 ;(HR:1.6, p=0.03) in model 1 but also R status 
(for R1/2/x HR:1.7, p=0.0006), grade (Weiss >6 and Ki67>20%, HR:1.3, p=0.06) in model 2. 
Conclusion: mENS@T classifications and GRAF parameters (Grading, R status, Age, and 
Functional symptoms) were found to best stratify the prognosis of advanced ACC patients.   
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Introduction  
 
 Adrenocortical carcinoma (ACC) is a rare malignancy with an estimated incidence of 
0.7–2.0 cases per million habitant per year (1, 2). ACC is considered one of the most 
aggressive solid tumor in oncology as testified by a 5-year survival below 15% for metastatic 
patients in four registries (3-6). Historically, ACC prognosis has been shown to be mainly 
driven by the presence of metastases and tumor resectability (7,8). More recently, the 
European Network for the Study of adrenal Tumors (ENS@T) classification of TNM stage 
and the resection status have refined prognostication (5, 6, 9, 10).  
Advanced ACC, defined as tumor stage III, in case of loco-regional spread, or stage 
IV, in case of distant metastases, represent 18-26% and 21-46% of ACC patients at 
diagnosis, respectively (3-6). Treatment options of these patients are limited (11-13) and no 
predictors of response is validated. The best way to stratify stage III and/or IV ACC patients 
prognosis is a matter of debate. Indeed, several studies have suggested that stage III 
patients with positive lymph nodes or vena cava invasion could have a similar prognosis than 
stage IV patients (9, 14, 15).  In stage IV ACC patients, the number of tumor affected organs 
has been reported to be of value in refining the prognosis of these patients as well (16). In 
addition, several studies suggested that age, secretion of hormones, Weiss score and/or 
proliferative index and the resection (R) status may also affect the prognosis of these 
patients (10, 17-20). An improved prognostic stratification is therefore needed to better 
understand the heterogeneity of prognosis in advanced ACC as illustrated by the 2 to 190 
months range overall survival reported in studies investigating treatment with mitotane (21-
26). 
The objective of this retrospective study was to refine the prognostic classification of 
advanced stage III and synchronous stage IV ACC patients. To achieve this goal, the 
ENS@T registry, encompassing a large number of ACC treated in expert centers from four 
European countries, was utilized. 
 
 
Patients and Methods 
 
Patients and data collection 
 
From January 1, 2000 to December 31, 2009, 463 patients with stage III or IV ACC 
followed in 16 expert referral centers of four European countries (Germany, France, Italy and 
Netherlands) were consecutively registered in a central computerized database: the 
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European network for the Study of Adrenal tumors (ENS@T) ACC Registry. Inclusion criteria 
were: confirmed histological diagnosis of ACC, stage III-IV at imaging and/or surgery 
performed within 3 months of primary diagnosis, age above 18 years and availability of 
follow-up data.  
Data collected included the following items at the time of diagnosis: age, gender, 
modality of tumor diagnosis (as defined by: incidental, symptom- or, hormone-related to 
tumor mass or other/unknown),  items of ENS@T or UICC TNM classifications (tumor size, 
invasion in adjacent tissue/organs or vena cava/renal vein, lymph node or distant 
metastases), tumor grading based on the pathological primary tumor analysis (defined by the 
median Weiss score (≤6/>6) or median Ki67 percentage (<20%/≥20%), R status at first 
surgery including the primary and metastasis (complete resection: R0; microscopic residual 
resection: R1; macroscopic residual disease: R2, resection not known: Rx).  
All parameters were captured based on per-investigator file and collected through a 
dedicated e-CRF.  
Both registries had been approved by the local ethics committees of all partaking 
centers and all included patients had provided written informed consent. 
 
Evaluation of different stage III-IV definitions and tumoral grading systems  
 
 
Since recent publications have suggested that tumors with N1 status or venous 
invasion could behave like stage IV metastatic disease, but also that the number of 
metastatic organs in stage IV ACC patients could help refining the classification (14-16), we 
first attempted to validate the best way to stratify the TNM of advanced stage III-IV ACC 
patients. Four different TNM classification systems were analyzed prior the final prognostic 
analysis: UICC, ENS@T classifications (6), but also two proposed modified ENS@T 
classifications (mENS@T) that classify either N1-Nx patients or venous invasion as stage IV 
and categorize stage IV according to the number of tumor organs (Figure 1). Selection and 
combination of parameters was performed graphically, using Kaplan-Meier and the Hall-
Wellner confidence interval of each curve. The parameters that were selected to best reflect 
tumor burden were those allowing the greatest discrimination of patients in terms of OS, 
graphically.  
Based on previous reports that suggest a prognostic role for the Weiss score and or 
proliferative index in advanced ACC patients (18, 27), we also first attempted to validate the 
best way to classify the pathological parameters as a Grading system for advanced stage III-
IV ACC patients according to the median Weiss score and or Ki67 index based on the 
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primary tumor analysis (Figure 2). Like for tumor burden, selection of parameters to express 
tumoral grade was performed graphically using Kaplan-Meier curves.  
 
Statistical analysis  
Descriptive analyses were performed using mean and standard-deviation for 
quantitative variables, and comparisons were performed using Student test (or non-
parametric Wilcoxon test if non-normally distributed). Qualitative variables were expressed in 
percentage and comparisons were performed using chi-square test.  
The primary endpoint was overall survival (OS), defined as the interval between date 
of stage III and IV ACC diagnosis and death of any cause. Surviving patients were censored 
at the date of last follow-up. Follow-up data were last updated for November 2012. The 
median follow-up was estimated by the reverse Kaplan-Meier method (Schemper’s method). 
Survival rates and 95% confidence interval were estimated by the Kaplan-Meier 
method. The log-rank test was used to compare survival curves. Parameters significantly 
associated with OS in univariate analysis (p<0.05) were further tested in the multivariate 
analysis. Hazard-ratio (HR) and 95% confidence interval (95%CI) were estimated using 
Cox’s proportional hazards regression model at multivariate analysis, with the lowest risk 
group as the reference group. All tests were two-sided. 
The following variables were analysed for their potential prognostic value at univariate 
analysis: age (<50 or >50 years), gender, modality of diagnosis (tumor mass, incidental 
mass, hormonal hypersecretion), tumor size (0-50 mm, 50-100 mm, 100-200 mm and 
>200mm), best staging system as defined above, type of organ involved (lung, liver, bone, 
distant lymph nodes), R status and pathological grading  as defined above.  
Two multivariate analyses were performed: model 1 called “prior-surgery” analysed all 
prognostic parameters available at the time of ACC diagnosis. Model 2 called “post-surgery” 
analysed all prognostic parameters including the grading and R status. Statistical analysis 
was conducted using SAS software version 9.2.  
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Results 
 
Population characteristics and follow-up data 
 
The following exclusion criteria were applied to the 463 cases reviewed: age younger than 18 
years old (15 patients), loss to follow-up (4 patients). Therefore, 444 patients constitute the 
studied population: 210 (47%) were classified ENS@T stage III and 234 (53%) were stage 
IV. The main clinical features are summarized in Table 2. Briefly, the majority of patients 
were females (61%) with a median age of 51±14 years. Symptoms related to tumor mass 
were present in 163 (37%), hormonal hypersecretions were present in 144 (32%) patients 
including cortisol hypersecretion in 116 (80%) patients.  
 Based on TNM staging, 11 (2%) were staged as T1, 97 (22 %) as T2, 140 (32%) as 
T3, and 196 (44%) as T4, respectively. Positive regional lymph nodes (N1) as defined by 
both imaging and pathology were found in 98 (22%) cases. Lung, liver, or bone metastases 
were found in 152 (34%), 125 (28%) and 32 (7%) of cases, respectively. In stage IV patients, 
the number of involved organs including the primary and the N status was 2 in 119 (27%), 
and at least 3 in 111 (26%) patients. R status was recorded in 279 (62%) of patients and an 
R0 status was achieved in 152 cases of them (54%) including the surgery of the primary or 
the primary and additional organs in 109 or 43 patients, respectively. Fifty-four patients (all 
stage IV) do not underwent surgery. 
 Weiss score was captured in 327 cases (73%) and was found above 6 in 153 (47%) 
tumors. Ki67 index was captured in 226 patients (50%) and found above 20% in 123 (54%) 
of cases.  
The median follow-up of patients was 55.2 months. Median overall survival was 24 
months. The 1-, 2- and 5-yr survival rates were 71%, 50% and 27%, respectively. Three 
hundred and one patients (68%) died during the time of the study. Among the 143 patients 
still alive at the time of data freeze: 76 (53%) were alive with metastatic or recurrence 
disease and 63 (44%) without evidence of disease, status was unknown in 4 patients. Death 
was ACC-related in all cases except in six. 
 
Evaluation of the best TNM and pathological classifications in advanced ACC patients  
Both ENS@T and the mENS@T classification, as defined in Materials and Methods, 
were found more informative than UICC (Figure 1). Finally, because the first mENS@T 
classification was found to better stratify the prognosis of stage III-IV ACC patients we finally 
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used the following mENS@T classification as defined by: stage III (T3-4N0M0) or, stage IVa, 
IVb, IVc according to the number of tumor organs involved including the primary tumor and 
lymph node status as “organ”: 2, 3 or >3, respectively (Supplementary Figure 1 a-b, Table 1). 
Regarding the grading, prognostic information but also the number of data available was 
taken into account. Both Ki67 and the Weiss score significantly discriminate OS outcome at 
univariate analysis. However, Ki67 capture was lacking in a significant number of patients. 
Weiss score and/or Ki67 were available in 350 patients and the combination of the two 
pathological parameters (Weiss ≤ 6 and Ki67<20 vs Weiss >6 or Ki67≥20) allowed to 
significantly separate two subgroups of patients, in terms of OS (Figure 2a-c). We finally 
classified the grading of advanced ACC patients according to the following classification as 
defined by: Weiss score > 6 or Ki67 ≥ 20% against Weiss score and Ki67 below these 
thresholds.  
 
Prognostic factors for overall survival  
 
 Univariate analysis (Table 3) 
 
At univariate analysis, the following parameters were found to be significantly 
inversely associated with overall survival (table 2): age > 50 years (p=0.005), the presence of 
symptoms related to tumor mass (p=0.005) or hormonal hypersecretion at diagnosis 
(p=0.0005), ENS@T, mENS@T classification (P<0.0001), R status (R1 status (p=0.007), or 
R2 (p<0.0001) or Rx (p<0.001)), Weiss score >6 (p=0.03) and Ki67  20% (p=0.003). Within 
the mENS@T classification, stage III, IVa, IVb, and IVc were found to be significantly 
associated with OS (p<0.001). Specifically, 2-yr OS was 72%, 42%, 22% and 12% for stages 
III, IVa, IVb and IVc and the 5-yr OS was 49%, 15%, 11% and 0% for stages III, IVa, IVb and 
IVc, respectively.  
 
 
Multivariate analysis: model 1 and model 2 (Table 4) 
 
At multivariate analysis within model 1, the following parameters were found 
significantly and independently associated with an increased risk of death: age > 50 years 
(p<0.0001), the presence of symptoms related to tumor mass (p=0.01) or hormonal 
hypersecretion at diagnosis (p=0.03), the mENS@T stage (all p<0.0001).  
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Within model 2, the following parameters were found significant associated to an 
increase of risk of death: age > 50 years (p<0.01), the presence of symptoms related to 
tumor mass (p=0.01) or hormonal hypersecretion at diagnosis (p=0.04), the mENS@T stage 
(all P<0.0001), the R status (p=0.0006). The HR of tumoral grade (Weiss >6 and/or Ki67  
20%) reached 1.3, with a p-value that tended to be significant (p=0.06).  
In the following section the acronym GRAF for Grading, Resection status, Age, 
Functional symptoms is grouped together to refer to these four parameters. 
 
 
Combination of prognostic parameters   
 
We then attempted to refine the prognostic classification of ACC, combining 
mENS@T stage with the GRAF parameters Presence of age >50 yrs and/or functional 
symptoms was first combined with mENS@T stages within model 1 (Figure 3). Presence of 
unfavourable Grading or R status was subsequently combined with mENS@T stages within 
model 2 (Figure 4).   
Figure 3 and 4 shows these GRAF parameters significantly affect the prognosis of 
mENSAT stage III or IVA. Five-yr OS of mENS@T stage III was 49% but ranges from 68%, 
when age was below 50 yrs and the tumor incidental  (Figure 3A) within model 1 to 22% 
when tumoral grading and R status were unfavourable within model 2 (Figure 4A).  
Five-years-OS of mENS@T stage IVa was 15% but ranged from 0 to 55% when age 
and functional symptoms were unfavourable or favourable within model 1 (Figure 3B) 
respectively, and ranged from 16 to 46% when tumoral grading and R status were 
unfavourable or favourable within model 2 (Figure 4B). 
 
 
Discussion 
 
Based on the largest cohort of patients with advanced ACC investigated so far, this 
collaborative study of the ENS@T network allows to refine the prognostic classification of 
advanced ACC patients as defined by stage III or synchronous stage IV. A new mENS@T 
TNM classification for advanced ACC patients is proposed as well as four additional 
prognostic parameters named “GRAF parameters” confirmed as critical: Grading (G), R 
status (R), age (A) and presence of functioning symptoms, as defined as tumor- or hormone-
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related symptoms at diagnosis (F). Of note, the clinical presentation of advanced 
synchronous ACC in our series is in agreement with previous reports and do not suggest 
bias in enrolment of this retrospective series of patients (4, 6, 10, 16).  
Tumor stage, as best defined by ENS@T classification, was confirmed as the 
keystone of the prognostic stratification of advanced ACC patients. Due to the high number 
of patients enrolled, we were able to further investigate the prognostic role of the N status 
together with venous invasion. We identify a deleterious prognostic role of the N1 status in 
the range of stage IV ACC patient prognosis as previously reported (9, 14) In addition, we 
confirm the prognostic value of the number of tumor organs including the primary but also the 
presence of lymph nodes (16). On the basis of these results, we herein elaborate a new 
prognostic TNM categorisation of advanced ACC patient, the mENS@T classification, that 
allows to significantly discriminate the prognostic outcomes of four categories of advanced 
ACC patients named stage III, IVa, IVb, IVc with 5-yrs OS of 49%, 15%, 11% and 0%, 
respectively. In this new classification the N1 status shifts tumours from the ENS@T stage III 
to the mENS@T stage IV category (i.e. stage IVa if isolated). By contrast, the prognosis of 
ACC patients with venous invasion was found consistent with other subgroups of the stage III 
N0. However, the fact that the presence of invasion to renal vein or vena cava could not be 
accurately documented in all cases, because it was just introduced in 2009 (6) constitutes a 
limitation of our study. In addition, it should be kept in mind that the N classification used in 
our study refers to both imaging and pathological classifications and future refinements are 
expected. From a therapeutic standpoint, these results may suggest that the surgery of ACC 
primary tumor including venous invasion is better handled by ACC surgeons than lymph 
node dissection whose putative role has been only be recently underlined (15, 28).  
In addition to the mENS@T classification, four parameters named GRAF parameters are 
validated for the first time as additional complementary prognostic parameters in large series 
of advanced ACC patients after adjustment for tumor burden. GRAF parameters were found 
to significantly affect the prognosis of each mENSAT stage that should now be reported in all 
studies that question the role of therapeutic intervention in this rare cancer. To make this new 
GRAF parameters applicable for physicians in their routine practice but also due to the 
limited number of patients, we decided to test the prognostic influence of the GRAF 
parameters within most numerous mENS@T stages namely stage III or IVa . The 5-yr OS 
prognosis of stage III patients was found to range between 60-70% in <50 yrs-old patients 
with an incidentally discovered ACC or with R0 status and favourable tumoral grading but 
dropped to 22% when postoperatively the tumoral grading and R status were both found 
unfavourable. Within stage IVa patients, the 5-yrs OS prognosis was 15% but was found to 
range from 0 to 55% in patients with favourable or unfavourable GRAF parameters, 
suggesting again an overlap between stage III and IVa patients. These results strongly 
suggest the added value of these GRAF parameters to refine the prognostic stratification of 
advanced ACC patients and the need for a standardized characterization of each of them.  At 
the end of the day, our results suggest that a 2 month difference in overall survival in phase 
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III trial, as recently reported in the FIRMACT trial, could be easily explained by unbalanced 
stratification for key prognostic parameters rather than therapeutic intervention. Age was 
found prognostic in some previous studies dealing with early or all stage ACC patients (4, 17, 
23) but not all (16). It was expressed as a binomial parameter in this study and whether it 
reflects the host, presence of comorbidities, or is a marker of the tumor biology requires 
further investigations. The presence of symptoms whatever the subtype, tumor- or hormone-
related, was also found to affect the prognosis with an identical prognostic influence. 
Hormonal work-up of ACC patients has been standardized for several years now and most 
recent series suggest a deleterious prognostic impact of cortisol secretions (17, 19). Future 
studies should investigate more precisely how far the magnitude and subtypes of secretions 
affect the prognosis (17, 19). In the same line, the general status and presence and type of 
tumor-related symptoms should now be more precisely defined (4, 6, 10, 16). The prognostic 
role of the mitotic index but also of the Ki67 even after adjustment to the stage has been 
suggested in previous reports (18, 27, 29). Some authors even proposed proliferative index 
as a more informative driver of the ACC prognostic classification than TNM stage (18, 27). 
We do not confirm this hypothesis in advanced ACC patients, especially as a far as a more 
accurate mENS@T classification is used. For reasons related to the limited number of 
patients with available Ki67 index, we decided to define the grading as a combination of the 
medians of the Weiss score and/or Ki67 index. Finally, among the GRAF parameters, 
grading was found to bring the weakest prognostic information. Whether the weak influence 
of the grade in our study is explained by a lower prognostic influence of the Weiss score in 
comparison with Ki67 index as suggested by univariate analysis in our study, methodological 
issues including absence of standardisation but also lack of pathological data in all patients, 
or a lower informative value of the primary tumor analysis in advanced ACC, remains to be 
explored. Standardization of Weiss criteria total score reading and proliferative index analysis 
in future pathological report is expected to represent a step forward in the evaluation of the 
prognostic influence of Weiss score and or proliferative index in advanced ACC patients. 
Although the authors consider Ki67 as more informative and despite the fact that Ki67 was 
found significant in a limited subgroup of advanced ACC with Ki67 available at multivariate 
analysis (data not shown), we suggest to use the combination of these parameters in 
advanced ACC patients until additional data are provided. 
A lower number of studies have focused on the prognostic role of the R status and its 
role is debated since found prognostic in some studies (4, 9, 30) but not all (16). Indeed, R 
status can be considered as a surrogate of the tumor burden but also testifies of the surgeon 
expertise which objective analysis is difficult. R0 status was found a major prognostic 
parameter in our study. Interestingly, at univariate analysis, both the R0 status achieved after 
the resection of the primary but also the primary and metastases was significant, suggesting 
that the benefit of the R0 status applies not only to the primary but also to the overall tumor 
mass (data not shown). Obviously clinicians should ensure that life expectancy and hazards 
of such intervention do not jeopardize the initial medical management.  
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Strengths of this study include the large number of patients based on national expert 
European networks together with prolonged follow-up allowing robust conclusions in this rare 
cancer. Limitations of this study include its retrospective nature, absence of pathological 
reports for all patients. Standardization and further validations of the mENS@T-GRAF 
parameters are however needed within  prospective cohort of patients as well as the analysis 
of the added value of the recently published molecular classification of ACC patients (31). 
 
Conclusion 
 
 To conclude, we validate a new mENSAT classification for advanced ACC and four 
additional prognostic “GRAF” parameters that include the grading, R status, Age and 
Functional status. This new mENS@T-GRAF system allows to refine the prognosis of 
advanced ACC patients and is expected to impact the design of future protocols, the 
interpretation of retrospective studies and to help in the development of biomarkers. 
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Figure 1: Overall survival according to UICC, ENS@T and two m-ENS@T TNM 
classification  in 444 avanced ACC patients :  
(A) overall survival (OS) according to UICC stage;  
(B) OS according to ENS@T;  
(C) OS according to m-ENS@T (modified-stage III and modified-stage IV).  
mENS@T classifications were built as follows: in the first mENS@T classification, stage III 
was split into two subgroups according to the N status (N0 or, N1-Nx status respectively). In 
the second mENS@T classification, stage III was split into two subgroups according to the 
venous invasion status (absence or presence of venous invasion) and compared to stage IV 
prognosis. In addition, stage IV was categorized into subgroups according to the number of 
tumor organs involved. Finally, the first mENSAT classification was found to best 
discriminate the outcome of advanced ACC patients 
 
Figure 2: Overall survival of patients according Weiss score, Ki 67 or the combination 
in 350 advanced ACC patients:  
(A) Weiss score alone (< 6 vs > 6)  
(B) Ki-67 (< 20% vs >20%) 
(C) combination of the two parameters (Ki-67 < 20 and Weiss < 6 vs Ki-67 > 20 or Weiss > 
6). 
Three different classifications were analysed prior the final prognostic analysis including: 
Weiss score as defined by global median score < 6 vs > 6, Ki67 as defined by a percentage 
< 20% vs > 20% or the combination of Weiss score and Ki67 (as defined by a score < 6 and 
Ki67 percentage < 20% or the presence of one of the two parameters). Patients whose 
Weiss score and Ki-67 were both missing were excluded from the analysis. 
 
Figure 3: Kaplan Meier curves of overall survival according to age and modality of 
diagnosis (Model 1) 
(A) mENS@T stage III  
(B) mENS@T stage IVa 
Prognostic factors (PF) number is calculated based on the presence or absence of age>55 
yrs, and/or symptoms at diagnosis 
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Figure 4: Kaplan Meier curves of overall survival according to the tumoral grade 
(Weiss ≤ 6 and Ki<20 vs Weiss >6 and or Ki>20) and resection status (R0 vs R1,R2, Rx) 
(Model 2) 
(A) mENS@T stage III  
(B) mENS@T stage Iva 
Prognostic factors (PF) number is calculated based on the presence or absence of  Weiss >6 
and or Ki>20 , and or  R1,R2, Rx 
 
 
 
 
Supplementary Figure 1:  
 
(A) Overall survival according to the N status of stage III and the number of organs 
involved of stage IV ACC patients  
(B) Overall survival according to the venous invasion status of stage III and   the 
number of organs involved of stage IV ACC patients  
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Table 1: Stage definitions in the Union for International Cancer Control (UICC), European 
Network for the Study of @drenal tumor (ENS@T) and the modified ENS@T (mENS@T), as 
defined in Materials and methods 
 
         
 
 
 
 
T1: tumor ≤ 5cm; T2: tumor > 5 cm; T3: tumor infiltration in surrounding tissue histologically proven; T4: tumor invasion in 
adjacent organs or venous tumor thrombus in vena cava or renal vein. Venous tumor thrombus is only a criterion in the ENS@T 
classification.  
 
N0: negative lymph nodes; N1: positive lymph nodes 
M0: absence of distant metastases; M1 presence of distant metastases 
  
Staging Definition
UICC 
III T3N0, N1
IV T3N1, T4, M1
ENS@T
III T3-4, N1
IV T1-4, N0 or N1,M1
mENSAT
III T3-4, N0
IVa T1-T4, N1 or M1 (2 organs including N)
IVb T1-T4, N0 or N1, M1 (3 organs)
IVc T1-T4, N0 or N1, M1 (> 3 organs)
 18 
Table 2: Main clinical and pathological characteristics of 444 advanced ACC patients 
 
 
 
Parameters n of patients (%)
n of evaluable 
patients
Patients 444 444
Age(yrs)
<50 200 (45%)
> 50 244 (55%)
Gender
Male 173 (39%)
Female 271 (61%)
Modality of diagnosis
Tumoral mass 163 (37%)
Hormonal secretion 144 (32%)
Incidenatally 65 (15%)
Other or unknown 72 (16%)
ENS@T stage
III 210 (48%)
IV 234 (52%)
modified ENS@T stage (mENS@T)
III 177 (40%) 
IVa  139 (31%)
IVb  75 (17%)
IVc  53 (12%)
Tumor (T)
T1 11 (2%)
T2 97 (22%)
T3 140 (32%)
T4 196 (44%)
Regional lymph nodes (N1)
Yes 98 (22%)
No 202 (45%)
Unknown 144 (32%)
Organ metastases (M1)
Lung 
Yes 152 (34%)
No 292 (65%)
Liver
Yes 125 (28%)
No 319 (72%)
Bone 
Yes 32 (7%)
No 412 (93%)
R status
R0 152 (34%)
R1 34 (8%)
R2 93 (21%)
Rx 165 (37%)
Weiss score
6 174 (53%)
>6 153 (47%)
Ki 67 (%)
<20 103 (46%)
20 123 (55%)
444
444
444
300
444
444
444
444
237
226
444
444
444
 19 
 
Table 3: Significant prognostic factors on overall survival at univariate analyses  
 
Parameters 
n of patients  
(%) 
HR (95%CI) 
p value  
(univariate)  
Age (yrs)       
<50  200 1   
>50  244 1.4 (1.1-1.9) 0.005 
Modality of diagnosis       
Incidental 65 1   
Tumoral 163 1.7 (1.2-2.6) 0.005 
Hormonal hypersecretion 144 2.0 (1.4-3.0) 0.0005 
ENS@T stage       
III 210 1   
IV 234 3.1 (2.4-3.9) <0.0001 
modified ENS@T stage (mENS@T)       
III 177 1  
IVa  139  2.5 (1.9-3.3) <0.0001 
IVb  75  3.9 (2.8-5.4)  <0.0001 
IVc  53  5.1 (3.5-7.4)  <0.0001 
R status       
R0 152 1   
R1 34 1.8 (1.2-2.9) 0.007 
R2 93 3.1 (2.3-4.3) <0.0001 
Rx 165 2.1 (1.5-2.7) <0.001 
Weiss score       
6 174 1   
>6 153 1.3 (1.02-1.7) 0.03 
Ki-67%       
<20 103 1   
>20 123 1.6 (1.2-2.3) 0.003 
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Table 4: Multivariate analyses (model 1 and 2) 
 Model 1 (N=444 pts) Model 2 (N=349pts) 
 Hazard 
ratio 
95% CI p Hazard ratio 95% CI p 
Age  
  <50 yrs  
  ≥ 50 yrs  
 
1 
1.6 
 
1 
1.3-2.1 
 
 
p<0.0001 
 
1 
1.4 
 
1 
1.1-1.8 
 
 
0.01 
Diagnosis modality  
 Incidentally  
 Tumoral  
 Hormonal hypersecretion  
 Other or unknown 
 
1 
1.6 
1.6 
1.2 
 
1 
1.1-2.5 
1.03-2.3 
0.8-1.9 
 
 
0.01 
0.03 
0.42 
 
1 
1.7 
1.6 
1.1 
 
1 
1.1-2.7 
1.01-2.5 
0.7-1.8 
 
 
0.01 
0.04 
0.75 
Modified ENS@T stage  
  III 
  IVa 
  IVb 
  IVc 
 
1 
2.6 
3.8 
4.9 
 
1 
2.0-3.5 
2.7-5.3 
3.4-7.2 
 
 
p<0.0001 
p<0.0001 
p<0.0001 
 
1 
2.1 
2.7 
3.7 
 
1 
1.5-2.9 
1.8-4.0 
2.4-5.8 
 
 
p<0.0001 
p<0.0001 
p<0.0001 
Tumoral grade 
Weiss ≤ 6 and Ki<20 
Weiss >6 and or Ki>20 
NA 
 
1 
1.3 
 
1 
0.98-1.7 
 
 
0.06 
R status  
  R0 
  R 1 2 x 
NA 
 
1 
1.7 
 
1 
1.3-2.3 
 
 
0.0006 
 
Model 1: prognostic model with clinical variables, without pathology and R status,  
Model 2: prognostic model with clinical variables, with pathology and R status,  
  NA= not applicable 
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Figure 1:  
A: UICC stage  
 
B: ENS@T stage  
 
C: modified ENS@T (mENS@T)  
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Figure 2:  
A: According to the Weiss score only  
 
B: According the Ki67 score only 
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C: OS according the combination of Weiss score and Ki67index  
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Figure 3:  
A: mENS@T stage III ATTENTION LA LEGENDE NO COLLE PAS/ ENLEVER FDR ET METTRE 
SYMPTOM PRESENCE-ABSENCE 
 
B: mENS@T stage IVa  ATTENTION LA LEGENDE NO COLLE PAS/ ENLEVER FDR ET METTRE 
SYMPTOM PRESENCE-ABSENCE 
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Figure 4  
A: mENS@T stage III 
 
B: mENS@T stage IVa 
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Appendix  
 
Supplementary figure 1:  
 
A 
 
 
B  
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